Rabbit Anti-Human Thymocyte Immunoglobulin (rATG) for Rescue Treatment of Chronic Antibody-Mediated Rejection (cAMR) After Pediatric Kidney Transplantation

Trial Profile

Rabbit Anti-Human Thymocyte Immunoglobulin (rATG) for Rescue Treatment of Chronic Antibody-Mediated Rejection (cAMR) After Pediatric Kidney Transplantation

Completed
Phase of Trial: Phase IV

Latest Information Update: 04 May 2017

At a glance

  • Drugs Antithymocyte globulin (Primary) ; Bortezomib; Prednisolone; Rituximab
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 May 2017 New trial record
    • 03 May 2017 Results presented at the 2017 American Transplant Congress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top